Generate a tailored SOP for Dr. Alfredo Addeo. Improve your application with a focused, well-structured draft.
Alfredo Addeo is a Consultant Oncologist specializing in tumor immunology and immunotherapy. He completed his training in Italy and has experience of four years in a laboratory in Turin, focusing on cellular immunity and the lack of responses in cancer, particularly pancreatic cancer involving dendritic cell IL-18 binding protein. After his time in Italy, he transitioned to the UK, where he took on a consultant role at Lincoln Bristol University Hospital, primarily dealing with thoracic malignancies. In 2017, he moved to Geneva and continued his work, aiming to identify biomarkers to support clinical trials in thoracic cancers. His research centers on predictive and prognostic biomarkers for immunotherapy in non-small cell lung cancer (NSCLC). Over the years, Addeo has published numerous papers exploring the role of inflammatory circulating biomarkers and their impact on the efficacy of immunotherapy. Some of his notable publications include studies on prognostic factors in patients with advanced lung cancer receiving chemoimmunotherapy and the implications of systemic inflammation on treatment outcomes.
Includes Department of Management, Finance, Economics, and Statistics programs. GMAT is strongly encouraged but not mandatory for most GSEM masters.